Hims & Hers launched GLP-1 prescriptions in May 2024 at $199 per month and built $225 million in revenue from that business in a single calendar year — on a legal window that closed in October 2024 when the FDA removed semaglutide from its shortage list. The compounding business that powered that growth attracted two FDA warning letters in September 2025, a terminated Novo Nordisk partnership, and a court-tested enforcement campaign against bulk compounders. What exists in 2026 is a materially different platform: a telehealth company now selling branded Wegovy and Ozempic at self-pay cash prices, with compounding reserved for narrow provider-determined clinical exceptions. How that pivot affects patients, what the pricing looks like today, and where the platform earns and does not earn its subscription fee is what this review covers.
Summary
Hims & Hers is a publicly traded telehealth company (NYSE: HIMS, founded 2017, IPO 2021) that transitioned from compounded semaglutide to branded FDA-approved GLP-1 medications following FDA enforcement actions and a March 2026 settlement with Novo Nordisk. It now sells Wegovy and Ozempic at self-pay cash prices, with licensed providers conducting remote intake and prescribing decisions.
- Current offering (as of Q2 2026): Branded Novo Nordisk products — Wegovy (injectable and pill), Ozempic (injectable) — starting at approximately $149 per month at self-pay prices; compounding reserved for providers who determine clinical necessity on a case-by-case basis under 503A rules.
- GLP-1 program launched: May 2024 with compounded injectable semaglutide at approximately $199 per month.
- FDA enforcement: Two warning letters issued September 9, 2025 — one each to Hims and Hers separately — citing false and misleading claims, specifically that site language implying compounded semaglutide was "the same as" Ozempic or Wegovy violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act.
- Novo Nordisk relationship: Initial partnership announced April 2025, terminated by Novo Nordisk in June 2025 over compounding concerns, re-established via settlement March 2026.
- 2024 financials (SEC filing): Total revenue $1.5 billion, GLP-1-related revenue approximately $225 million; company-projected weight-loss revenue of $725 million for 2025, with full-year 2025 revenue guidance of $2.3 to $2.4 billion.
- Reviews: Trustpilot ratings of 3.4 to 3.8 across Hims and Hers properties (7,000+ reviews combined); recurring complaints center on subscription transparency, care-team continuity, and the abrupt transitions during the compounding-to-branded pivot.
- Hard limit: GLP-1 medications are prescription drugs. No telehealth platform, including Hims & Hers, can legally dispense them without an individual prescribing decision by a licensed provider following a clinical evaluation.
For background on how semaglutide works mechanistically and what the trial evidence shows, see the semaglutide complete guide. For a comparison of costs across GLP-1 programs and what insurance typically covers, see the peptide cost and insurance guide.
Who Hims & Hers Is
Hims & Hers Health Inc. launched in 2017 as a direct-to-consumer telehealth company offering men's health products, primarily hair loss and erectile dysfunction treatments, at a time when the subscription wellness market was expanding rapidly. The company went public in January 2021 via a SPAC merger, trading on the New York Stock Exchange under the ticker HIMS. Its business model is built on asynchronous telehealth: patients complete an online intake questionnaire, a licensed provider reviews responses and issues a prescription if appropriate, and medication ships via mail-order pharmacy. There are no in-person visits. The care team interaction happens primarily through a messaging interface.
The company operates two consumer-facing brands: Hims (men) and Hers (women). Both brands now offer GLP-1 weight loss programs. Weight loss became the dominant growth driver after the May 2024 GLP-1 launch, accounting for a substantial share of the company's 69% year-over-year revenue increase in 2024.
That growth did not come without regulatory friction. The company's compounded semaglutide offering sat in a legal gray zone from the moment it launched, and it remained there until the FDA's October 2024 shortage-list decision made the gray zone considerably smaller.
GLP-1 Program Timeline: May 2024 to Current State
May 2024 — Program launch: Hims & Hers introduces injectable compounded semaglutide at approximately $199 per month, prescribing it through its asynchronous platform. The product is manufactured by partner compounding pharmacies operating under 503A rules, which allow pharmacies to prepare compounded drugs when an FDA-approved equivalent is on the shortage list. Wegovy had been on the shortage list since 2022.
October 2024 — FDA removes semaglutide from shortage list: The FDA declares that semaglutide is no longer in short supply. Under the applicable rules, licensed 503A compounders have a defined wind-down period to stop producing bulk compounded semaglutide; 503B outsourcing facilities are required to stop immediately. The compounding industry files suit to challenge the removal, arguing the FDA acted prematurely. Courts ultimately side with the FDA. For Hims & Hers, this decision signals the end of the compounded-at-scale business model it launched on.
February 2025 — FDA formally ends shortage designation: The FDA's February 21, 2025 declaration triggers a formal compliance deadline and sends Hims shares down approximately 25% in a single trading session. The company states it intends to comply.
April 2025 — Initial Novo Nordisk partnership: Hims & Hers and Novo Nordisk announce a collaboration to sell branded Wegovy and other Novo products through the telehealth platform.
June 2025 — Novo terminates partnership: Novo Nordisk publicly ends the collaboration, citing Hims & Hers' continued promotion of what it characterizes as "illegal mass compounding and deceptive marketing." The relationship lasts approximately one month before collapsing.
September 9, 2025 — FDA warning letters: The FDA issues two warning letters, one to Hims and one to Hers, citing specific website language as false or misleading under federal law. The phrases "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients" appear in the letters as examples of claims that improperly implied equivalence between compounded products and FDA-approved drugs. The agency required a written response within 15 working days describing corrective steps taken.
March 2026 — Settlement and strategic pivot: Hims & Hers announces a settlement with Novo Nordisk and a full strategic shift for its U.S. weight loss business. The company will stop promoting compounded GLP-1s as a primary offering, transition existing patients to branded medications in consultation with their provider, and reserve 503A compounding only for cases where a licensed provider determines a commercially available product cannot meet a patient's clinical needs. The company begins offering Wegovy injections and the newly launched Wegovy pill, plus Ozempic injections, at self-pay cash prices.
What They Prescribe Today
As of the date of this article, Hims & Hers is primarily a distributor of branded FDA-approved GLP-1 products. The lineup includes Wegovy injectable semaglutide in all approved dosages, the oral Wegovy pill, and Ozempic injectable semaglutide (note: Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction, not for weight loss; prescribing it for weight management is an off-label decision made by the individual provider).
Compounded semaglutide remains available in a narrower capacity under the 503A personalization pathway. Federal law permits a licensed 503A pharmacy to prepare a compounded drug for an individual patient when a provider determines that the commercially available product cannot meet that patient's clinical needs. Hims & Hers intends to use this pathway for patients for whom branded product dosing, formulation, or other clinical factors genuinely create a gap. What this means in practice is still being operationalized. Patients considering this route should understand the distinction: personalization under 503A is a legal pathway, but not every claimed customization represents a meaningful clinical difference. The FDA has been explicit that "same active ingredient" arguments do not grant compounded products equivalence to approved drugs.
Intake happens entirely online: a questionnaire covering weight, health history, and medications, reviewed asynchronously by a licensed provider. There are no video appointments by default, though the platform offers messaging access to a care team.
Pricing Tiers
Pricing as of early 2026 under the new branded model:
- Wegovy injectable or Wegovy pill: Starting at approximately $149 per month at self-pay cash prices. These are Novo Nordisk's own products; the price reflects Hims & Hers negotiating access to Novo's self-pay pricing tier, similar to what other telehealth platforms offer.
- Membership fee: A separate membership starting at $39 for the first month, then approximately $149 per month thereafter, layered on top of medication cost in some program structures. This fee covers 24/7 care-team messaging access.
- Bundled plans: Earlier program structures offered "weight loss kits" starting around $69 per month on a 10-month prepaid plan, which included compounded product at that time. The current equivalent under the branded model has not been definitively repriced as of publication.
- Compounded semaglutide (residual, provider-determined): Pricing not publicly listed as a standard tier; available only following a provider clinical determination.
- Insurance: Hims & Hers operates on a cash-pay model. It does not coordinate insurance billing. If a patient wants insurance coverage for Wegovy, they need to go through a path that involves their insurance provider and a prescriber who can submit a prior authorization.
For a broader look at what GLP-1s cost across programs and what insurance pathways exist, the peptide cost and insurance guide covers the landscape in detail.
Customer Review Patterns
Across Trustpilot (3.4 to 3.8 stars, 7,000+ combined reviews as of mid-2025) and consumer review platforms, a consistent set of themes appears. These patterns predate the 2026 pivot and will likely take time to resolve under the new model.
Where reviews are positive: Patients who successfully received a prescription and began treatment generally report that the intake process is fast compared to finding an in-person provider with availability. Shipping reliability gets positive marks in most reviews. Some reviewers specifically note that the async model fits their schedule.
Where reviews are negative: Subscription and billing practices are the single most common complaint. Multiple reviewers report being charged for recurring subscriptions without adequate advance notice. Cancellation difficulty and refund denials on unused or ineffective product are a recurring thread. These issues are not unique to the GLP-1 line, but they are prominent.
GLP-1-specific friction: During the 2024-2025 compounded-to-branded transition, a meaningful subset of patients reported receiving communications about medication changes without clear explanation of what they were receiving or why. One category of complaint involves intake forms generating prescriptions for "Medication Kit 6" or similar internal designations that were opaque to the patient. Patients transitioning from compounded to branded product during 2026 have reported confusion about cost changes.
FTC context: The FTC has been investigating Hims & Hers' subscription cancellation practices. That investigation was ongoing as of mid-2025. It does not relate specifically to GLP-1 prescribing but adds a layer of operational scrutiny that prospective subscribers should be aware of.
For comparison with another large telehealth GLP-1 platform, see the Found GLP-1 telehealth review and the WeightWatchers Clinic GLP-1 review, which cover different prescribing models and care structures.
Where It Earns Its Place
Hims & Hers does two things well relative to the alternatives.
Speed of access. In a primary-care system where obesity medicine appointments can have waits of weeks to months, the ability to complete an online intake and receive a prescribing decision within one to two business days is a real practical advantage for patients who have already done their research and are appropriate candidates. The provider is still making an individual clinical decision; this is not a vending machine. But the friction is lower.
Cash-pay pricing on branded product. The March 2026 Novo Nordisk settlement gives Hims & Hers access to self-pay Wegovy pricing that the company says matches what other telehealth platforms charge. For patients who do not have insurance coverage for Wegovy and cannot afford the $1,300+ retail price at traditional pharmacies, a $149/month self-pay path through a telehealth platform is genuinely meaningful, assuming the prescriber determines the medication is appropriate.
Where It Does Not
No ongoing clinical monitoring. GLP-1 medications require follow-up. Weight trajectory, side effects, dose adjustments, and blood work (particularly thyroid function if there is any risk history, and kidney/pancreas markers for patients in those risk categories) are not systematically built into the Hims & Hers model. The care team messaging is available, but it is not the same as a structured monitoring protocol with a provider who sees the patient.
Compounding trust deficit. The September 2025 FDA warning letters and the Novo Nordisk public termination statement are on the public record. Patients evaluating any residual compounded product offered through this platform should weigh that history. The FDA's concern was not only that compounded semaglutide lacked the same safety and efficacy evidence as approved products, but specifically that Hims & Hers made claims implying it was equivalent when it was not. The 503A personalization pathway that remains is legally distinct from the bulk compounding the warning letters targeted, but patients should ask direct questions about what specifically is being compounded, why, and what evidence supports that the customization is clinically meaningful rather than a marketing differentiation.
Subscription design. The billing structure, including membership fees, medication costs, and subscription auto-renewal terms, has generated enough complaints and enough regulatory attention to be a material concern before signing up. Read the cancellation policy before subscribing.
Frequently Asked Questions
Is GLP-1 treatment available without a prescription?
No. Semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and all approved GLP-1 receptor agonists are prescription drugs in the United States. No telehealth platform, supplement company, or online vendor can legally dispense them without an individual prescribing decision by a licensed provider.
Can Hims & Hers still prescribe compounded semaglutide?
As of the March 2026 strategic shift, compounded semaglutide is no longer the primary offering. Residual access exists under the 503A framework for individual patients whose provider determines that available branded products cannot meet clinical needs. This is not the same as the prior model where compounded semaglutide was the standard-of-care default at $199 per month.
What does the FDA warning letter mean for patients already taking Hims semaglutide?
The September 2025 warning letters addressed marketing claims, not product safety for patients already in treatment. Patients who were receiving compounded semaglutide from the platform at that time were not subject to a recall. The appropriate step for any patient with questions about their ongoing treatment is to contact their provider directly.
Is personalized compounding under 503A different from what the FDA warned about?
Yes, but the distinction requires care. Section 503A of the FD&C Act permits a licensed pharmacy to prepare compounded drugs for an individual patient based on a provider's determination of clinical need. This is a legal pathway. The FDA's concern with Hims & Hers was mass compounding without adequate individual clinical justification, combined with marketing that implied equivalence to approved drugs. The key standard is whether the compounding represents a genuine clinical need for that individual patient, not a business model scaling compounded product to any patient willing to pay.
Does Hims & Hers accept insurance?
No. It is a cash-pay platform. Insurance coverage for GLP-1 medications typically requires prior authorization, documentation of BMI or weight-related comorbidities, and submission through a provider who participates in the insurance network. The self-pay pricing Hims & Hers offers through its Novo Nordisk agreement may still be lower than what an uninsured patient pays retail at a traditional pharmacy.
What should I look for in any telehealth GLP-1 program?
A licensed provider making an individual prescribing decision (not an automated approval); a clear protocol for dose escalation and follow-up; transparent pricing with no hidden membership fees; a straightforward cancellation process; and explicit acknowledgment of whether any compounded product is involved and why.
Conclusion
Hims & Hers built a large GLP-1 business by moving faster than the regulatory environment could stop it. The compounded semaglutide window was real — for a period, the shortage list made bulk compounding legal — but the platform's marketing overstated what it was selling, the FDA said so formally, and the business model required a full reset. What exists in 2026 is a more conventional telehealth model selling branded Novo Nordisk product at self-pay cash prices, with a much smaller residual compounding window. That is a materially different platform than what launched in May 2024, and reviews from the transition period reflect considerable patient confusion.
For a patient who is an appropriate clinical candidate, wants fast asynchronous access to a branded GLP-1 prescription, and understands that the care model is predominantly digital messaging rather than ongoing physician oversight, the current Hims & Hers offering is a real option worth comparing. The $149/month self-pay Wegovy price point is competitive. The subscription billing concerns documented in customer reviews and FTC scrutiny are not hypothetical risks. Those two things can both be true at the same time.
GLP-1 medications are prescription drugs. The decision to start, continue, or stop them requires a licensed provider with access to your full health history, not a 10-question intake form reviewed asynchronously. Telehealth can be a legitimate access pathway for the right patient. It is not a workaround for the clinical evaluation that a drug of this class requires.
Medical Disclaimer: The content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 receptor agonists, including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), are prescription-only medications in the United States. A licensed healthcare provider must evaluate your individual health status, medical history, and current medications before prescribing any GLP-1 therapy. Do not start, stop, or modify any prescription medication without guidance from your physician or other qualified healthcare professional. If you are pregnant, planning to become pregnant, or breastfeeding, discontinue GLP-1 therapy and consult your provider, as these medications are not approved for use during pregnancy. This article does not endorse any specific telehealth platform, pharmacy, or treatment program.
